Using the predictive algorithm of Rothbard and Taylor (1988 . EMBOJ. 7:93) and the primary structure of gp63 (Button, L., and M.R. McMaster. 1988. J. Exp. Med. 167:724; Miller, R.A., S.G. Reed, and M. Parsons . 1990. Mol. Biochem. Parasitol. 39:267) we have been able to delineate the structures of a number of gp63 T-cell epitopes which stimulate the proliferation of CD4' cells . One of these synthetic antigens, inoculated subcutaneously with adjuvant, was shown to specifically induce proliferation of the Thl subset and provided immunoprotection against two species of Leishmania parasites . R ecent studies by Russell and Alexander have demonstrated that immunization ofmice with the major cell surface glycoprotein gp63, results in cell-mediated immunity and protection from Leishmania mexicana infections (1). These findings suggested the possibility that the structures of the gp63 T cell epitopes might be predicted and chemically synthesized using the known Leishmania major primary structure (2) and the predictive algorithm proposed by Rothbard and Taylor (3) . We report here that three synthetic T cell epitopes of the immunoprotective gp63 molecule stimulate proliferation of murine CD4+ cells and that one specifically stimulates Thl cells, the subset proposed to be responsible for immunoprotection in mice (4) . The latter epitope was further shown to protect vaccinated mice from cutaneous leishmaniasis.
Summary
Using the predictive algorithm of Rothbard and Taylor (1988 . EMBOJ. 7:93) and the primary structure of gp63 (Button, L., and M.R. McMaster. 1988 . J. Exp. Med. 167:724; Miller, R.A., S.G. Reed, and M. Parsons . 1990 . Mol. Biochem. Parasitol. 39:267) we have been able to delineate the structures of a number of gp63 T-cell epitopes which stimulate the proliferation of CD4' cells . One of these synthetic antigens, inoculated subcutaneously with adjuvant, was shown to specifically induce proliferation of the Thl subset and provided immunoprotection against two species of Leishmania parasites . R ecent studies by Russell and Alexander have demonstrated that immunization ofmice with the major cell surface glycoprotein gp63, results in cell-mediated immunity and protection from Leishmania mexicana infections (1) . These findings suggested the possibility that the structures of the gp63 T cell epitopes might be predicted and chemically synthesized using the known Leishmania major primary structure (2) and the predictive algorithm proposed by Rothbard and Taylor (3) . We report here that three synthetic T cell epitopes of the immunoprotective gp63 molecule stimulate proliferation of murine CD4+ cells and that one specifically stimulates Thl cells, the subset proposed to be responsible for immunoprotection in mice (4) . The latter epitope was further shown to protect vaccinated mice from cutaneous leishmaniasis.
Materials and Methods
Animals. Mice were purchased from either The Jackson Laboratory (Bar Harbor, ME) or from the Charles River Breeding laboratories (St . Constant, Quebec) and used at 8-10 wk of age. BALB/c mice for vaccine trials were bred in-house. Complement-mediated Cell Lysis. Lysis was carried out using 5 x 105 lymph node cells incubated with either alloanti-Thy-1 antisera, anti-L3T4' or anti-Lyt-2.2' mAbs (Cedarlane Laboratories Ltd., Hornby, Ontario) for 60 min at 4°C, followed by addition of 10% rabbit complement for 60 min at 37°C.
Lymphokine Determinations. 11,2 and 11,4 were assayed using the IL2-and 114-dependent CTLLr2 cell line (ATCC TIB 214). Specific neutralization was achieved with an anti-11,2 antibody, S4B6 (17), or with the anti-IL-4 antibody 11BIl (ATCC HB). 11,3 was determined using the IL3-dependent cell line DA-1. Results were expressed as units oflymphokine extrapolated from standard recombinant interleukin curves.
Immunoprotection Trial. Four groups of eight female BALB/c mice were used in this study. Each group was injected subcutaneously with 100 hg of test peptide in a temperature-dependent sol gel transition adjuvant, 8% Poloxamer 407 (BASF, Wayandotte, Ludwigshaven, FRG) with exception of the control group, which received only adjuvant . After 6 wk the mice were inoculated subcutaneously in the hind quarters with 2 x 10" stationary phase L. major promastigotes. A similar study used L. mexicana promastigotes and CBA mice. Progress ofdisease was monitored by measurement of lesion diameter beginning at 4 wk after inoculation .
Results and Discussion
The primary structure of L. major gp63, as described by Button and McMaster (2) and corrected by Miller et al. (5) , was used along with the predictive algorithm of Rothbard and Taylor (3) to select seven peptide sequences as potential T cell epitopes (PT1-4 and PT6-8) . The ability of these peptides to stimulate lymphocyte proliferation was tested by immunization of mice, followed by in vitro challenge of isolated lymph node cells with the test peptides. Fig . 1 shows the dose-response curves after challenge ofprimed lymph node cells with the immunizing peptides. Three peptides were found to be stimulatory. The overlapping peptides PT3 and PT4, which cover a highly conserved region believed to be responsible for zinc binding (6, 7) , stimulated proliferation in cells derived from BALB/c (H-2d), A/J (H-2'), and CBA (H-2k) mice but not in C57BL/6 (H-2b) lymphocytes . Peptide PT6 was pan-specific for this collection of mouse haplotypes, stimulating lymphocytes from all strains. Verification that j3H]TdR incorporation was associated with T cell proliferation was provided by T cell-specific depletion using antiThy-1 antisera (data not shown) or anti-L3T4+ mAb and complement (Fig. 2) . While only data for the peptide PT6 are shown, similar proliferation data were obtained for peptides PT3 and PT4 and in experiments with lymphocytes from the other responding mouse strains. These data show that the proliferating cells are primarily of the CD4+ subset . Evidence was also obtained that the B cell population was unaffected by the depletion procedure by using the B cell mitogen LPS (Fig. 2) .
Recent findings have suggested that proliferation of either the CD4 * Thl or Th2 subsets determines whether an immunoprotective or disease exacerbating condition is found after infection with Leishmania major (4) . A study of lymphokine production, after challenge oflymph node cells with the stimulatory peptides, showed that only PT3 was capable of stimulating 11,2 (Table 1) and that none of the epitopes produced measurable IL4. It could be concluded that under the immunization protocol used, PT3 specifically induced proliferation of the CD4+ Thl subset (8) . These findings, together with the fact that gp63 was known to elicit protective cell-mediated immunity in mice (1), strongly supported the candidacy of the PT3 epitope as a potential vaccine for cutaneous leishmaniasis .
Results ofimmunoprotection experiments using these synthetic epitopes showed that a molecularly defined vaccine was Table 1 a strong possibility. BALB/c mice were injected with a single dose of either peptide PT3, PT4, or PT6 in adjuvant, or with adjuvant alone, and after a 6 wk rest were infected with 2 x 10°stationary phase . L. major promastigotes. Fig 3 shows results of the first study using the adjuvant Poloxamer 407 . Lesion development was evident at 4 wk in control animals, as well as in animals inoculated with PT4 and PT6 but not in the group immunized with PT3 . At 6 wk the number of infected animals in previously infected groups increased, along with the average lesion size, while no evidence of infection could be found in the group immunized with PT3 plus adjuvant . Not until 2 mo after inoculation was there evidence of lesion development in the latter group. This appeared to be the end of a period of premunition induced by the single subcutaneous injection of antigen . A second experiment, using the same protocol but with a slightly higher adjuvant concentration (12 .5%), provided further verification of the immunoprotective capacity of PT3 . Not only was this peptide once again shown to limit the disease, but half the animals vaccinated with PT3 cured of disease 12-16 wk after inoculation with parasites. Results using Leishmania mexicana and the previous protocol were even more convincing, with complete lack of disease in the vaccinated group 3 mo after parasite challenge. That these findings were not entirely related to the Poloxamer 407 adjuvant was shown by conducting another L. major experiment but replacing Poloxamer with CFA. No sign of disease was found in vaccinated animals 5 wk after parasite inoculation, while all controls showed lesion development . Nonetheless an interesting result from the second L. major experiment with Poloxamer indicated that the use of adjuvant was an important determinant in the outcome of these subcutaneous vaccinations. When PT3 was injected in the absence of adjuvant, an exacerbation in lesion growth was observed (data not shown) . This result mimicked a previously described disease exacerbation produced in BALB/c mice after subcutaneous vaccination with irradiated L. major promastigotes (9, 10) . A possible explanation for these results has recently been proposed suggesting that adjuvant could affect the physiological state of APCs, stimulating production of costimulatory factors appropriate for Thl, rather than Th2 cell proliferation (11) .
While long-term immunity was not attained with a single injection, these results are very promising and experiments to further characterize the immunoprotective utility of the synthetic peptides are now in progress . It should be feasible to assess whether the same epitope can induce protection or exacerbation dependent upon the route or mode of administration, and conversely, whether several types of epitopes can exist within the gp63 structure. Indeed preliminary evidence has indicated that using the Poloxamer adjuvant both forms of epitope are found in gp63, arguing against the general utility of large, undefined, recombinant antigens. Experimentation can now proceed with single epitopes, rather than complex structures containing both an array of undefined T cell epitopes as well as oligosaccharides. The findings reported here show that a molecularly defined approach to a solution of these problems is not only feasible but critical for the development of vaccines against cutaneous leishmaniasis.
